Abstract
Pharmacological therapy is a critical step in the management of individuals with the metabolic syndrome (MetS) when lifestyle modifications cannot achieve the therapeutic goals. However, it has been well-documented that there is no single best therapy other than weight loss, and that treatment should be targeted at individual components of the MetS. The objective of this study was to investigate the treatment of individual components of the MetS in a population-based sample of individuals with clustering MetS components. In a cross-sectional population-based survey, we studied a randomly collected sample of men and women who had participated in the baseline survey of a community-based program in three Central Iranian counties in 2000 to 2001. Demographic data, medical status, and drug history were obtained by questionnaire. We evaluated the association between clustering of the MetS components and pharmacological treatment of cardiovascular risk factors. The most common pharmacologic agents prescribed for individuals with the MetS were beta-blockers (72.8%), followed by lipid-lowering agents (36%) with no significant gender difference. A high level of compliance with drug treatment was noted. Further research is warranted to understand the compliance behavior of patients with the MetS.
Highlights
Despite the international campaign against noncommunicable diseases (NCD) over the past 20 years, cardiovascular diseases (CVD) remain the leading cause of death in most of the Western world, with a rapidlyAbbreviation: NCD, Non-communicable disease; CVD, cardiovascular disease; MetS, metabolic syndrome; LDL, low density lipoprotein cholesterol; IHHP, Isfahan healthy heart program; Body mass index (BMI), body mass index; WC, Waist circumference.increasing trend in developing countries (Alsaraj et al, 2009)
The Isfahan healthy heart program (IHHP) was conducted in three Central Iranian counties; Isfahan and Najaf-Abad were intervention areas and Arak served as a reference area
The MetS was documented in 2832 participants (22.8%), including 2124 women (33.4%) and 780 men (11.7%)
Summary
Despite the international campaign against noncommunicable diseases (NCD) over the past 20 years, cardiovascular diseases (CVD) remain the leading cause of death in most of the Western world, with a rapidlyAbbreviation: NCD, Non-communicable disease; CVD, cardiovascular disease; MetS, metabolic syndrome; LDL, low density lipoprotein cholesterol; IHHP, Isfahan healthy heart program; BMI, body mass index; WC, Waist circumference.increasing trend in developing countries (Alsaraj et al, 2009). Abbreviation: NCD, Non-communicable disease; CVD, cardiovascular disease; MetS, metabolic syndrome; LDL, low density lipoprotein cholesterol; IHHP, Isfahan healthy heart program; BMI, body mass index; WC, Waist circumference. The metabolic syndrome (MetS) is associated with increased risk of developing NCD, notably diabetes and CVD (Grundy et al, 2005). It has been demonstrated that many middle-aged individuals with the MetS are at increased 10-year absolute risk of CVD (Grundy et al, 2005). Individuals with coronary heart disease, stroke or diabetes are in the high-risk category and should be treated (Deedwania and Gupta, 2006). The age-standardized prevalence of the MetS was about 34.7% based on the ATP III criteria, and was higher in women, in urban areas, and in the 55 to 64 year
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call